GRIFOLS S A/S (NASDAQ:GRFS) Upgraded to “Strong-Buy” by BidaskClub

BidaskClub upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a buy rating to a strong-buy rating in a report issued on Saturday morning, BidAskClub reports.

Several other research firms also recently weighed in on GRFS. JPMorgan Chase & Co. raised shares of GRIFOLS S A/S from a neutral rating to an overweight rating and lifted their price target for the company from $21.00 to $22.50 in a research note on Thursday, June 27th. ValuEngine downgraded shares of GRIFOLS S A/S from a hold rating to a sell rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research raised shares of GRIFOLS S A/S from a sell rating to a hold rating in a research note on Wednesday, July 24th. Three research analysts have rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $20.75.

GRIFOLS S A/S stock opened at $21.82 on Friday. The company’s 50 day moving average is $21.50. The company has a quick ratio of 0.95, a current ratio of 2.68 and a debt-to-equity ratio of 1.38. GRIFOLS S A/S has a fifty-two week low of $17.42 and a fifty-two week high of $23.03. The company has a market capitalization of $15.32 billion, a P/E ratio of 18.65, a PEG ratio of 1.34 and a beta of 1.11.

GRIFOLS S A/S (NASDAQ:GRFS) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.25. GRIFOLS S A/S had a net margin of 11.82% and a return on equity of 14.38%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. As a group, research analysts expect that GRIFOLS S A/S will post 1.26 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of GRFS. Norges Bank bought a new stake in shares of GRIFOLS S A/S during the fourth quarter valued at approximately $57,748,000. JPMorgan Chase & Co. raised its stake in GRIFOLS S A/S by 856.0% in the first quarter. JPMorgan Chase & Co. now owns 1,558,478 shares of the biotechnology company’s stock worth $31,340,000 after buying an additional 1,395,461 shares in the last quarter. FIL Ltd raised its stake in GRIFOLS S A/S by 12.2% in the first quarter. FIL Ltd now owns 8,170,942 shares of the biotechnology company’s stock worth $164,318,000 after buying an additional 887,474 shares in the last quarter. AKO Capital LLP raised its stake in GRIFOLS S A/S by 5.5% in the second quarter. AKO Capital LLP now owns 12,562,923 shares of the biotechnology company’s stock worth $265,078,000 after buying an additional 654,497 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in GRIFOLS S A/S by 9.7% in the first quarter. First Trust Advisors LP now owns 5,125,719 shares of the biotechnology company’s stock worth $103,078,000 after buying an additional 453,032 shares in the last quarter. 19.01% of the stock is owned by hedge funds and other institutional investors.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: What is the Moving Average Convergence Divergence (MACD) oscillator?

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.